Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 11, 2023
Reporting Period: Single event date (April 11, 2023)
Business Context: The Company is an emerging growth company focused on oncology. This filing reports the presentation of clinical data at the American Association of Cancer Research (AACR) Annual Meeting 2023.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is limited to reporting a specific corporate event.
Material Changes
No financial material changes are reported in this document. The material event is the scientific presentation of data regarding the Company's lead candidate, INB03.
Outlook, Management Commentary, and Risks
- Event Details: On April 11, 2023, the Company announced it is presenting data on INB03, a dominant-negative TNF inhibitor of soluble TNF (sTNF).
- Therapeutic Focus: The data pertains to the treatment of high-risk MUC4 expressing HER2+ and triple-negative breast cancer.
- Location: American Association of Cancer Research Annual Meeting 2023 in Orlando, Florida.
- Exhibits: A press release detailing the event is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the specific clinical data and results presented in the attached press release (Exhibit 99.1).
- Confirm the current development status and regulatory pathway for INB03 in HER2+ and triple-negative breast cancer.
- Review the Company's most recent 10-Q or 10-K for up-to-date financial liquidity and cash runway, as this 8-K contains no financial figures.